CYTX - Cytori Therapeutics, Inc.

[Henrique Costa]

Profile: Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution System family of products, which processes patients' cells at the bedside in real time.
Market Cap: 110M
Website: http://www.cytoritx.com/

Trading Thesis:

Mid term speculative play, based on TA and FA.

The Short term technical layout is not much appealing, but despite that the stock has been reacting well on its 200 ema and consolidating this level  (3.00-3.50) for a while. If it remains above 3.00 my take is that we're going to watch a big move to the upside.

Fundamentals are not solid yet, but it has good prospects.
Zacks have recently upgraded CYTX to Buy (from Neutral) giving it a target price of $8:

Outlook


We continue to be very positive on Cytori Therapeutics and
believe the company s Celution System, a better mousetrap
for quickly and efficiently harvesting adult stem cells, will
see sales ramp significantly over the next few years. Sales
of the system have been tracking with our expectations.
Ultimately, the clinical data will determine the pace at which
the ramp continues. So far, the clinical data has been
exciting, and with several investigator-sponsored programs
ongoing. Additional data expected over the next few years
will have an immediate impact on the financial results.

Today s price represents a very attractive entry point in our
view. We are maintaining our Outperform rating and $8
target.

Trading Plan:
Buy 5% @ open, stop @ 2.65 and limit sell @ 7.50
(include in Speculative Portfolio)